potassium chloride has been researched along with Chorea Disorders in 2 studies
Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.
potassium chloride : A metal chloride salt with a K(+) counterion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The proposed pathogenesis of Sydenham's chorea (SC) is an autoantibody-mediated basal ganglia dysfunction." | 1.33 | Serum from Sydenham's chorea patients modifies intracellular calcium levels in PC12 cells by a complement-independent mechanism. ( Cardoso, F; Guimarães, MM; Romano-Silva, MA; Teixeira, AL, 2005) |
| "Delayed-onset generalized dystonia and choreoathetosis then appeared." | 1.28 | Delayed onset movement disorders as a complication of central pontine myelinolysis. ( Ferrer, X; Julien, J; Tison, FX, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Teixeira, AL | 1 |
| Guimarães, MM | 1 |
| Romano-Silva, MA | 1 |
| Cardoso, F | 1 |
| Tison, FX | 1 |
| Ferrer, X | 1 |
| Julien, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Antibiotic Treatment Trial for the PANDAS/PANS Phenotype[NCT01617083] | Phase 2 | 47 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The CYBOCS is a clinician rated, semi-structured interview for rating the severity of OCD (Scahill, et al., 1997). Total scores range from 0 to 50, with higher scores representing greater severity. The total score is comprised of two subscores, obsessions and compulsions, each with a range of 0-25. (NCT01617083)
Timeframe: Before and after 4 week randomization
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | After 4 week randomization | |
| Azithromycin | 29.49 | 20.53 |
| Placebo | 28.43 | 23.45 |
The CGI-S scale is a 7-point clinician rating of severity of psychopathology. Severity ratings range from 1 (no illness) to 7 (extremely severe). This instrument has been successfully used in treatment studies (Cook, et al., 2001; Storch, et al., 2007). (NCT01617083)
Timeframe: Before and after 4 week randomization
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | After 4 week randomization | |
| Azithromycin | 5.24 | 4.06 |
| Placebo | 5.00 | 4.93 |
The Screen for Childhood Anxiety-Related Emotional Disorders (SCARED) is a 41-item parent and participant-completed tool used to measure symptoms of anxiety, including the most common symptoms of panic/somatic, generalized anxiety, separation anxiety, social phobia, and school phobia. Scores range from 0-82, with higher scores indicating more severe symptoms.The child and parent versions of the SCARED have moderate parent-child agreement and good internal consistency, test-retest reliability, and discriminant validity; it is also sensitive to treatment response (Birmaher et al. 1999). The target population for this rating is 8-18 years of age (Birmaher et al. 1997). The parent and child version of the SCARED were administered before and after week 4 randomization. This measure is not validated for use in 4-7 year olds. (NCT01617083)
Timeframe: Before and after 4 week randomization
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | After 4 week randomization | |
| Azithromycin | 31.82 | 30.88 |
| Placebo | 20.43 | 21.97 |
2 other studies available for potassium chloride and Chorea Disorders
| Article | Year |
|---|---|
Serum from Sydenham's chorea patients modifies intracellular calcium levels in PC12 cells by a complement-independent mechanism.
Topics: Adolescent; Animals; Antibodies; Basal Ganglia; Calcium; Child; Chorea; Complement System Proteins; | 2005 |
Delayed onset movement disorders as a complication of central pontine myelinolysis.
Topics: Athetosis; Chorea; Demyelinating Diseases; Dystonia; Female; Follow-Up Studies; Humans; Hypokalemia; | 1991 |